228 related articles for article (PubMed ID: 30033822)
1. Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons.
Busca A; Pagano L
Expert Rev Anti Infect Ther; 2018 Jul; 16(7):531-542. PubMed ID: 30033822
[TBL] [Abstract][Full Text] [Related]
2. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
3. A network meta-analysis of primary prophylaxis for invasive fungal infection in haematological patients.
Leonart LP; Tonin FS; Ferreira VL; Penteado STS; Wiens A; Motta FA; Pontarolo R
J Clin Pharm Ther; 2017 Oct; 42(5):530-538. PubMed ID: 28620958
[TBL] [Abstract][Full Text] [Related]
4. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R
Eur J Haematol; 2005 Sep; 75(3):227-33. PubMed ID: 16104879
[TBL] [Abstract][Full Text] [Related]
5. Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies.
Gamaletsou MN; Walsh TJ; Sipsas NV
Turk J Haematol; 2018 Mar; 35(1):1-11. PubMed ID: 29391334
[TBL] [Abstract][Full Text] [Related]
6. Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.
Lee CH; Lin C; Ho CL; Lin JC
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866872
[TBL] [Abstract][Full Text] [Related]
7. Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects.
Akan H; Antia VP; Kouba M; Sinkó J; Tănase AD; Vrhovac R; Herbrecht R
J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii5-16. PubMed ID: 24155144
[TBL] [Abstract][Full Text] [Related]
8. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation.
Michallet M; Ito JI
J Clin Oncol; 2009 Jul; 27(20):3398-409. PubMed ID: 19487382
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
10. Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies.
Murali S; Langston A
Transpl Infect Dis; 2009 Dec; 11(6):480-90. PubMed ID: 19725908
[TBL] [Abstract][Full Text] [Related]
11. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
[TBL] [Abstract][Full Text] [Related]
12. Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.
Epstein DJ; Seo SK; Brown JM; Papanicolaou GA
J Antimicrob Chemother; 2018 Jan; 73(suppl_1):i60-i72. PubMed ID: 29304213
[TBL] [Abstract][Full Text] [Related]
13. Invasive aspergillosis in patients with hematologic malignancies.
Wiederhold NP; Lewis RE; Kontoyiannis DP
Pharmacotherapy; 2003 Dec; 23(12):1592-610. PubMed ID: 14695039
[TBL] [Abstract][Full Text] [Related]
14. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients.
Wirk B; Wingard JR
Mycopathologia; 2009 Dec; 168(6):299-311. PubMed ID: 19247798
[TBL] [Abstract][Full Text] [Related]
15. [Invasive aspergillosis in the patient with oncohematologic disease].
Solano C; Vázquez L
Rev Iberoam Micol; 2018; 35(4):198-205. PubMed ID: 30554673
[TBL] [Abstract][Full Text] [Related]
16. Invasive fungal infections: managing the continuum of risk in HCT patients.
Duarte RF; Lyon S
Future Microbiol; 2017 Aug; 12():843-846. PubMed ID: 28685597
[TBL] [Abstract][Full Text] [Related]
17. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
[TBL] [Abstract][Full Text] [Related]
18. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014.
Morrissey CO; Gilroy NM; Macesic N; Walker P; Ananda-Rajah M; May M; Heath CH; Grigg A; Bardy PG; Kwan J; Kirsa SW; Slavin M; Gottlieb T; Chen S
Intern Med J; 2014 Dec; 44(12b):1298-314. PubMed ID: 25482742
[TBL] [Abstract][Full Text] [Related]
19. Pharmacist review of high-risk haematology outpatients to improve appropriateness of antifungal prophylaxis.
Reslan Z; Lindsay J; Kerridge I; Gellatly R
Int J Clin Pharm; 2020 Dec; 42(6):1412-1418. PubMed ID: 33009604
[TBL] [Abstract][Full Text] [Related]
20. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.
Pechlivanoglou P; Le HH; Daenen S; Snowden JA; Postma MJ
J Antimicrob Chemother; 2014 Jan; 69(1):1-11. PubMed ID: 23975736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
